The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | mLIPI as a predictor of nivolumab outcomes in advanced NSCLC
Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, discusses the use of the modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune-related adverse events in advanced non-small cell lung cancer (NSCLC). Speaking from the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland, Prof. O’Byrne also discusses the benefits of combining this measure with PD-L1 expression testing.
